License Fee-Royalties Sample Clauses

The License Fee-Royalties clause defines the financial obligations of the licensee to pay the licensor for the right to use certain intellectual property, such as patents, trademarks, or copyrighted materials. Typically, this clause outlines how royalties are calculated—whether as a percentage of sales, a fixed fee per unit, or a lump sum—and specifies the payment schedule and reporting requirements. Its core practical function is to ensure that the licensor is fairly compensated for the use of their intellectual property, while providing clear terms to prevent disputes over payment.
License Fee-Royalties. In addition to the Development Milestone Fee, and in consideration of the license rights granted to SciSparc as set forth under section 6 herein, SciSparc shall pay to Polyrizon the following royalties (the “Royalties”): 4.4.1. For sales of the Product by SciSparc, SciSparc shall pay Polyrizon an amount equal to 3.25% of the Net Income actually received by SciSparc. 4.4.2. For sales of the Product by a sublicensee of SciSparc, SciSparc shall pay Polyrizon an amount equal to 35% of the income actually received by SciSparc from the sublicensee.
View SourceView Similar (2)
License Fee-Royalties. In addition to the Development Milestone Fee, and in consideration of the license rights granted to Nurexone as set forth under section 6 herein, Nurexone shall pay to Polyrizon the following royalties (the “Royalties”): 4.4.1. For sales of the Product by Nurexone that generate an income of between US$ 50,000 and US$ 2,500,000 Nurexone shall pay Polyrizon an amount equal to 2.25% of the Net Income actually received by Nurexone. 4.4.2. For sales of the Product by Nurexone that generate an income of between US$ 2,500,000 and US$ 10,000,000 Nurexone shall pay Polyrizon an amount equal to 2.75% of the Net Income actually received by Nurexone. 4.4.3. For sales of the Product by Nurexone that generate an income greater than US$ 10,000,000 Nurexone shall pay Polyrizon an amount equal to 3.25% of the Net Income actually received by Nurexone. 4.4.4. For sales of the Product by a sublicensee of Nurexone, Nurexone shall pay Polyrizon an amount equal to 35% of the income actually received by Nurexone from the sublicensee.
View SourceView Similar (2)
License Fee-Royalties. 4.1 At the signing of this Agreement, the UBC Parties will pay Bionovo a one-time, non-refundable fee of US$150,000 at the signing of this agreement. Bionovo acknowledges that it received [*] of that payment before signing this Agreement, in consideration of its ongoing negotiation with the UBC Parties. 4.2 Upon the completion of the phase II trial, UBC will pay Bionovo an amount to be discussed at that time in US$ in order to complete the additional specific requirements for CMC by Taiwan DOH. The schedule for the payment of the amount US$ will be determined by a mutually agreed upon timeline. In the event Bionovo did not secure additional funding for the complete required CMC and ADMET, as required by US FDA, UBC will have the option to negotiate with Bionovo the independent completion the above mentioned CMC and ADMET work. The terms of exercising this option will be mutually agreed upon based on expense and scientific evaluation of the process by both parties. 4.3 UBC will pay to Bionovo a royalty fee (the "Royalty Fee") in the amount of [*] of total monetary consideration received by UBC for -------- * This information has been omitted and is subject to a request for confidential treatment with the Securities and Exchange Commission. Pharmaceuticals sold ("Net Sales"). However, if no patent(s) is granted in the territory to one of the Pharmaceuticals, the Royalty Fee for the said Pharmaceutical shall be [*] after five years from the time the product was launched. 4.4 Bionovo and its representatives (including auditors) will have the right to examine UBC's books and record at any reasonable time on reasonable notice for the purpose of verifying Net Sales. All expenses arising from the examination of UBC's accounts will be borne by Bionovo. However, if Net Sales reported to Bionovo are more than [*] less than Net Sales determined by independent auditors engaged by Bionovo, UBC will pay 100% of the expenses of the examination of UBC' accounts. All information and documents examined will be kept strictly confidential. 4.5 UBC will pay the Royalty Fee to Bionovo quarterly, within [45 calendar] days after the end of each calendar quarter. 4.6 All payments and transfers made by UBC to Bionovo will be subject to the relevant withholding taxes prescribed by R.O.C. law. 4.7 UBC will pay pursuant to Article 3, within 30 calendar days of the date of any reimbursement request, Bionovo's expenses related to (i) quarterly site visit of each of the clinical trials, (...
View SourceView Similar (2)
License Fee-Royalties. As additional consideration for the rights granted to the Distributor under this Agreement, (a) Distributor shall make a payment to Company of (i) US$ * on the Effective Date, (ii) US$ * within thirty (30) days following the completion of the efficacy and safety analysis of the European Phase III clinical trial of the Product in general surgery patients, (iii) US$ * within thirty (30) days of Regulatory Approval of the Product in the United States or the European Union, (iv) US$ * within thirty (30) days of Regulatory Approval of the Product in the Territory; and (b) Distributor shall pay Company a * royalty on Net Sales of the Product in the Territory. Distributor’s obligations under Section 7.1(b) shall continue for the longer of (a) ten (10) years from the First Commercial Sale of the Product in the Territory or (b) the expiration of the last to expire of the patents utilized by or in the Product in the Territory. * Certain information in this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
View Source
License Fee-Royalties 
View SourceView Similar (2)

Related to License Fee-Royalties

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • License Fees and Royalties Consistent with the applicable U.S. DOT Common Rules, the Recipient agrees that license fees and royalties for patents, patent applications, and inventions produced with federal assistance provided through the Underlying Agreement are program income, and must be used in compliance with federal applicable requirements.

  • License Fees If so provided in the Prospectus, the Depositor may enter into a Licensing Agreement (the "Agreement") with a licensor (the "Licensor") described in the Prospectus in which the Trust(s), as consideration for the licenses granted by the Licensor for the right to use its trademarks and trade names, intellectual property rights or for the use of databases and research owned by the Licensor, will pay a fee set forth in the Agreement to the applicable Licensor or the Depositor to reimburse the Depositor for payment of the expenses. If the Agreement provides for an annual license fee computed in whole or part by reference to the average daily net asset value of the Trust assets, for purpose of calculating the accrual of estimated expenses such annual fee shall accrue at a daily rate and the Trustee is authorized to compute an estimated license fee payment (i) until the Depositor has informed the Trustee that there will be no further deposits of additional Securities, by reference to an estimate of the average daily net asset value of the Trust assets which the Depositor shall provide the Trustee, (ii) thereafter and during the calendar quarter in which the last business day of the period described in clause (i) occurs, by reference to the net asset value of the Trust assets as of such last business day, and (iii) during each subsequent calendar quarter, by reference to the net asset value of the Trust assets as of the last business day of the preceding calendar quarter. The Trustee shall adjust the net asset value (Trust Fund Evaluation) as of the dates specified in the preceding sentence to account for any variation between accrual of estimated license fee and the license fee payable pursuant to the Agreement, but such adjustment shall not affect calculations made prior thereto and no adjustment shall be made in respect thereof. (17) Sections 2.05(a) and 2.05(b) are hereby amended and replaced in their entirety with the following:

  • License Fee The Licensee to shall make payment of the License Fee to Licensor on the date of this Agreement. All rights granted to Licensee by Producer in the Beat are conditional upon Licensee’s timely payment of the License Fee. The License Fee is a one-time payment for the rights granted to Licensee and this Agreement is not valid until the License Fee has been paid.

  • Earned Royalties In partial consideration of the License and subject to Sections 3.7 and 3.8, Company will pay to Penn: (i) a graduated royalty as set forth in the table below based upon worldwide annual Net Sales made by Company and its Affiliates (but not sublicensees) of any Designated Compound Sold for use in the Field of Use while covered in the country of Sale of expected use by a Valid Claim of the Assigned BMS Patents that is licensed to Company under the License (but no other Licensed Product): <$500 million [CONFIDENTIAL TREATMENT REQUESTED] /*/% >$500 million but <$750 million [CONFIDENTIAL TREATMENT REQUESTED] /*/% >$750 million but <$1 billion [CONFIDENTIAL TREATMENT REQUESTED] /*/% >$1 billion [CONFIDENTIAL TREATMENT REQUESTED] /*/% [CONFIDENTIAL TREATMENT REQUESTED] /*/ PATENT LICENSE AGREEMENT (ii) a royalty of [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of Net Sales made by Company and its Affiliates (but not sublicensees) for all Licensed Products that qualify as “Licensed Products” hereunder based on clause (b) of that definition and Sold while covered in the country of Sale of expected use by a Valid Claim of the Penn Existing Patents or Penn New Patents; provided that, notwithstanding any credits provided for in Section 3.7 but subject in all events to Section 3.8, royalties payable by Company for such Net Sales for such Licensed Products shall not be less than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%). Only one royalty shall be due hereunder on the Sale of the same unit of Licensed Product. If a royalty accrues to a Sale of a Licensed Product under both clause (i) and (ii) above, then the higher rate of clause (i) shall apply. Only one royalty shall be due hereunder on the Sale of a Licensed Product even if the manufacture, use, sale, offer for sale or importation of such Licensed Product infringes more than one Valid Claim of the Penn Patent Rights.